Cullinan Therapeutics, Inc. (CGEM)
(Delayed Data from NSDQ)
$7.88 USD
-0.20 (-2.48%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $7.89 +0.01 (0.13%) 7:28 PM ET
4-Sell of 5 4
F Value C Growth A Momentum D VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
CGEM 7.88 -0.20(-2.48%)
Will CGEM be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CGEM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CGEM
Wall Street Analysts Predict a 292.51% Upside in Cullinan Therapeutics (CGEM): Here's What You Should Know
CGEM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for CGEM
Cullinan Therapeutics management to meet virtually with Clear Street
Cullinan Therapeutics management to meet virtually with Clear Street
Upcoming Virtual Meeting for Cogent Biosciences (CGEM) Investors
Taiho Oncology and Cullinan Therapeutics Announce Acceptance of Abstracts for Zipalertinib at ...
Cullinan Therapeutics: Betting On Zipalertinib NDA Catalyst